3- (4- (2- hydroxyethyl)piperazin- 1- yl)- 7- (6- methoxypyridin- 3- yl)- 1- (2- propoxyethyl)pyrido(3,4- b)pyrazin- 2(1H)- one
structure in first source
Also Known As:
HMPPP-one; PF-03049423
Networked: 2
relevant articles (0 outcomes,
2 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
| 1. | Ischemic Stroke
09/01/2016
- " This was a multicenter, multinational, randomized, parallel group, controlled versus placebo, efficacy, and safety study of PF-03049423 for treatment of acute ischemic stroke. " 03/01/2016
- " PF-03049423 showed no therapeutic potential for acute ischemic stroke." 03/01/2016
- " The therapeutic potential of phosphodiesterase-5 inhibitor PF-03049423 was evaluated in a phase 2, multicenter, randomized, double-blind, placebo-controlled study of subjects with acute ischemic stroke ( http://www.clinicaltrials.gov, unique identifier: NCT01208233; http://www.clinicaltrialsregister.eu, EudraCT number: 2010-021414-32). "
|
| 2. | Stroke (Strokes)
|
|
Related Drugs and Biologics